These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 10408339

  • 1. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
    Moulard M, Mabrouk K, Martin I, Van Rietschoten J, Rochat H, Sabatier JM.
    J Pept Res; 1999 Jun; 53(6):647-55. PubMed ID: 10408339
    [Abstract] [Full Text] [Related]

  • 2. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N, Fantini J, Baghdiguian S, Mabrouk K, Tamalet C, Rochat H, Van Rietschoten J, Sabatier JM.
    Proc Natl Acad Sci U S A; 1995 May 23; 92(11):4867-71. PubMed ID: 7761414
    [Abstract] [Full Text] [Related]

  • 3. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
    Delézay O, Hammache D, Fantini J, Yahi N.
    Biochemistry; 1996 Dec 10; 35(49):15663-71. PubMed ID: 8961929
    [Abstract] [Full Text] [Related]

  • 4. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells.
    Barbouche R, Miquelis R, Sabatier JM, Fenouillet E.
    J Pept Sci; 1998 Dec 10; 4(8):479-85. PubMed ID: 9927254
    [Abstract] [Full Text] [Related]

  • 5. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
    Mabrouk K, Van Rietschoten J, Rochat H, Loret EP.
    Biochemistry; 1995 Jul 04; 34(26):8294-8. PubMed ID: 7599121
    [Abstract] [Full Text] [Related]

  • 6. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.
    Yahi N, Sabatier JM, Nickel P, Mabrouk K, Gonzalez-Scarano F, Fantini J.
    J Biol Chem; 1994 Sep 30; 269(39):24349-53. PubMed ID: 7929093
    [Abstract] [Full Text] [Related]

  • 7. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.
    Yahi N, Sabatier JM, Baghdiguian S, Gonzalez-Scarano F, Fantini J.
    J Virol; 1995 Jan 30; 69(1):320-5. PubMed ID: 7983725
    [Abstract] [Full Text] [Related]

  • 8. Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop.
    Carlier E, Mabrouk K, Moulard M, Fajloun Z, Rochat H, De Waard M, Sabatier JM.
    J Pept Res; 2000 Dec 30; 56(6):427-37. PubMed ID: 11152302
    [Abstract] [Full Text] [Related]

  • 9. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
    Barbouche R, Fenouillet E, Papandréou MJ, Kiény MP, Sabatier JM.
    J Pept Res; 1998 Oct 30; 52(4):283-8. PubMed ID: 9832306
    [Abstract] [Full Text] [Related]

  • 10. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
    Nehete PN, Vela EM, Hossain MM, Sarkar AK, Yahi N, Fantini J, Sastry KJ.
    Antiviral Res; 2002 Dec 30; 56(3):233-51. PubMed ID: 12406507
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F, Borman AM, Brand D, Girard M.
    AIDS Res Hum Retroviruses; 1999 May 20; 15(8):731-43. PubMed ID: 10357469
    [Abstract] [Full Text] [Related]

  • 14. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.
    Fantini J, Hammache D, Delézay O, Yahi N, André-Barrès C, Rico-Lattes I, Lattes A.
    J Biol Chem; 1997 Mar 14; 272(11):7245-52. PubMed ID: 9054420
    [Abstract] [Full Text] [Related]

  • 15. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells.
    Xiao X, Kinter A, Broder CC, Dimitrov DS.
    Exp Mol Pathol; 2000 Jun 14; 68(3):133-8. PubMed ID: 10816381
    [Abstract] [Full Text] [Related]

  • 16. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3.
    Hammache D, Piéroni G, Yahi N, Delézay O, Koch N, Lafont H, Tamalet C, Fantini J.
    J Biol Chem; 1998 Apr 03; 273(14):7967-71. PubMed ID: 9525894
    [Abstract] [Full Text] [Related]

  • 17. SPC3, a nontoxic peptide inhibitor of HIV infection.
    Sabatier JM, Baghdiguian S, Yahi N, Rochat H, Van Rietschoten J, Fantini J.
    In Vitro Cell Dev Biol Anim; 1995 Jun 03; 31(6):415-8. PubMed ID: 8589880
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
    Foda M, Harada S, Maeda Y.
    Microbiol Immunol; 2001 Jun 03; 45(7):521-30. PubMed ID: 11529558
    [Abstract] [Full Text] [Related]

  • 20. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
    Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, Desrosiers RC.
    J Virol; 2001 Apr 03; 75(8):3903-15. PubMed ID: 11264379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.